| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
111,521,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxxinity is a biotechnology company. Co.'s pipeline consists of five chronic disease product candidates including UB-311, which targets toxic forms of aggregated Ab in the brain to fight Alzheimer's Disease; UB-312, which targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's Disease and other synucleinopathies; an anti-tau product candidate that has the potential to address various neurodegenerative conditions; UB-313, which targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9, which targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
362,934 |
| Total Buy Value |
$0 |
$0 |
$0 |
$776,028 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
96,936 |
1,191,214 |
| Total Sell Value |
$0 |
$0 |
$168,588 |
$3,463,338 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
6 |
20 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Guirakhoo Farshad |
(Former) Chief Scientific Off. |
• • – |
2022-08-15 |
4 |
OE |
$0.57 |
$14,823 |
D/D |
26,005 |
66,005 |
|
- |
|
| Guirakhoo Farshad |
(Former) Chief Scientific Off. |
• • – |
2022-07-29 |
4 |
OE |
$0.57 |
$11,400 |
D/D |
20,000 |
40,000 |
|
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-06-16 |
4 |
B |
$1.99 |
$199,290 |
I/I |
100,000 |
51,737,344 |
2.64 |
- |
|
| Reese Lou |
Executive Chairman |
• • • |
2022-06-16 |
4 |
B |
$1.99 |
$199,290 |
I/I |
100,000 |
51,737,344 |
2.64 |
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-06-16 |
4 |
B |
$1.99 |
$199,290 |
D/D |
100,000 |
51,737,344 |
2.45 |
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-06-09 |
4 |
B |
$2.72 |
$29,852 |
I/I |
10,978 |
51,637,344 |
2.64 |
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-06-09 |
4 |
B |
$2.72 |
$29,852 |
D/D |
10,978 |
51,637,344 |
2.37 |
- |
|
| Reese Lou |
Executive Chairman |
• • • |
2022-06-09 |
4 |
B |
$2.72 |
$29,852 |
I/I |
10,978 |
51,637,344 |
2.64 |
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-06-08 |
4 |
B |
$2.95 |
$29,534 |
I/I |
10,000 |
51,626,366 |
2.64 |
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-06-08 |
4 |
B |
$2.95 |
$29,534 |
D/D |
10,000 |
51,626,366 |
2.37 |
- |
|
| Reese Lou |
Executive Chairman |
• • • |
2022-06-08 |
4 |
B |
$2.95 |
$29,534 |
I/I |
10,000 |
51,626,366 |
2.64 |
- |
|
| Guirakhoo Farshad |
Chief Scientific Officer |
• – – |
2022-05-03 |
4 |
OE |
$0.57 |
$5,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Reese Lou |
Executive Chairman |
• • – |
2022-04-27 |
4 |
AB |
$3.58 |
$17,222 |
I/I |
4,807 |
51,616,366 |
|
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-04-27 |
4 |
AB |
$3.58 |
$17,222 |
I/I |
4,807 |
51,616,366 |
|
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-04-27 |
4 |
AB |
$3.58 |
$17,222 |
D/D |
4,807 |
51,616,366 |
|
- |
|
| Reese Lou |
Executive Chairman |
• • – |
2022-04-26 |
4 |
AB |
$3.45 |
$62,468 |
I/I |
18,105 |
51,611,559 |
|
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-04-26 |
4 |
AB |
$3.45 |
$62,468 |
I/I |
18,105 |
51,611,559 |
|
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-04-26 |
4 |
AB |
$3.45 |
$62,468 |
D/D |
18,105 |
51,611,559 |
|
- |
|
| Hu Mei Mei |
See Remarks |
• • • |
2022-04-25 |
4 |
AB |
$3.37 |
$27,073 |
I/I |
8,038 |
51,593,454 |
|
- |
|
| United Biomedical Inc |
10% Owner |
– – • |
2022-04-25 |
4 |
AB |
$3.37 |
$27,073 |
D/D |
8,038 |
5,193,454 |
|
- |
|
| Reese Lou |
Executive Chairman |
• • – |
2022-04-25 |
4 |
AB |
$3.37 |
$27,073 |
I/I |
8,038 |
51,593,454 |
|
- |
|
| Powchik Peter |
Director |
– • – |
2022-03-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
225,858 |
|
- |
|
| Diamandis Peter |
Director |
• • – |
2022-01-24 |
4/A |
D |
$8.60 |
$2,688,867 |
D/D |
(312,659) |
430,604 |
|
- |
|
| Diamandis Peter |
Director |
– • – |
2022-01-24 |
4 |
OE |
$4.12 |
$2,688,865 |
D/D |
652,764 |
729,687 |
|
- |
|
| Guirakhoo Farshad |
(Former) Chief Scientific Off. |
• • – |
2022-01-13 |
4 |
OE |
$0.57 |
$5,700 |
D/D |
10,000 |
10,000 |
|
- |
|
81 Records found
|
|
Page 2 of 4 |
|
|
